Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on December 11, 2007
JNCI Journal of the National Cancer Institute 2007 99(24):1825-1827; doi:10.1093/jnci/djm264
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/24/1825    most recent
djm264v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Prowell, T. M.
Right arrow Articles by Stearns, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prowell, T. M.
Right arrow Articles by Stearns, V.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

EDITORIALS

Extended Adjuvant Therapy for Breast Cancer—How Much Is Enough?

Tatiana M. Prowell, Vered Stearns

Affiliation of authors: Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD

Correspondence to: Vered Stearns, MD, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Bunting-Blaustein Cancer Research Building, 1650 Orleans Street, Rm 145, Baltimore, MD 21231-1000 (e-mail: vstearn1@jhmi.edu).

The first 150 words of the full text of this article appear below.

Aromatase inhibitors are a class of drugs that inhibit the conversion of androgens to estrogen. They are generally regarded as the preferred first-line endocrine treatment for metastatic hormone receptor–positive breast cancer in postmenopausal women, in whom they produce outcomes that are equivalent or superior to those produced by tamoxifen (1). Tamoxifen, when given for 5 years to women with early-stage estrogen receptor–positive breast cancer, reduces the risk of recurrence by 41% and the risk of death by 33% and has long represented the standard of care for adjuvant endocrine therapy for both premenopausal and postmenopausal women (2). Given the superiority of aromatase inhibitors in the metastatic setting for postmenopausal women, three approaches to incorporate aromatase inhibitors into the adjuvant setting have been tested. One approach included the administration of an aromatase inhibitor for 5 years instead of 5 years of tamoxifen. A second approach tested switching . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Extended Adjuvant Therapy With Anastrozole Among Postmenopausal Breast Cancer Patients: Results From the Randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a
Raimund Jakesz, Richard Greil, Michael Gnant, Marianne Schmid, Werner Kwasny, Ernst Kubista, Brigitte Mlineritsch, Christoph Tausch, Michael Stierer, Friedrich Hofbauer, Karl Renner, Christian Dadak, Ernst Rücklinger, and Hellmut Samonigg On behalf of the Austrian Breast and Colorectal Cancer Study Group
J Natl Cancer Inst 2007 99: 1845-1853. [Abstract] [Full Text] [PDF]

IN THIS ISSUE
J Natl Cancer Inst 2007 99: 1821. [Extract] [Full Text] [PDF]